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  Open Access   
Abstract 
Systemic juvenile idiopathic arthritis is classified as an autoimmune entity 
and a subtype of juvenile idiopathic arthritis, although it has many features 
of autoinflammatory-type of diseases. This review article will elaborate on 
the disease’s pathogenesis and its proposed relation to autoinflammatory 
diseases including defective innate immunity and phagocytosis response 
leading excessive cytokine release. It also explains the disease’s epidemiolo- 
gy, clinical phenotype, diagnostic challenges, complications and current 
advancements in the treatment of systemic juvenile  idiopathic  arthritis, 
such as IL-1 and IL-6 antagonists and their impact on the disease trajectory. 
Care of patients with systemic juvenile idiopathic arthritis requires a com- 
prehensive multidisciplinary team to optimize the care and avoid complica- 
tions of the disease itself such as growth impairment, macrophage activa- 
tion syndrome or the complications of immunosuppressant and immuno- 
modulatory treatments. 
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Systemic juvenile idiopathic arthritis (sJIA) is a distinctive subtype of juvenile 
idiopathic arthritis (JIA), which is considered a systemic arthritis subtype ac- 
cording to the classification provided by the International League of Associa- 
tions for Rheumatology (ILAR) [1]. Various names and nomenclatures, includ- 
ing systemic juvenile rheumatoid arthritis, systemic juvenile chronic arthritis, 
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systemic-onset JIA and childhood-onset Still’s disease, have been used to de- 
scribe this condition, but sJIA is the preferred descriptive terminology [1]. Adult-
onset Still’s disease (AOSD) is a continuum of sJIA with similar physi- 
opathological and immunological characteristics, clinical phenotype, pharmaco- 
logical response and epidemiological characteristics, such as a lack of sex predi- 
lection, except for the age of onset [2] [3]. The clinical definition of the systemic 
arthritis subtype in accordance with the ILAR classification includes 2-week du- 
ration of fever and arthritis as cardinal features, as well as at least one of the 
following: hepatosplenomegaly, lymphadenopathy, serositis or typical rash [1]. 
Diagnosis is based largely on the identification of clinical criteria and exclusion 
of other serious conditions that mimic its symptoms, such as infection and ma- 
lignancy [4]. Early recognition of sJIA and initiation of proper treatment are 
considered critical to successfully controlling inflammation and disease, as well 
as potentially reducing long-term morbidity and mortality, particularly given the 
growing evidence of the benefit of biologic disease-modifying antirheumatic 
drugs (DMARDs) early in the course of the disease [5] [6] [7]. 
This review article will explore the most recent research on this disorder, 
mainly on the disease’s epidemiology, pathogenesis, clinical phenotype, labora- 
tory tests, complications and treatment of sJIA. The last section will review all 
aspects of caring for patients with sJIA that a paediatrician should know as well 
as supervising the care collaboratively with patients, families and other physi- 
cians and allied healthcare workers. 
2. Objectives 
After completing this article, the reader should attain the following goals: 
1) Understand the pathophysiology of sJIA and its complication, macrophage 
activation syndrome (MAS); 
2) Recognize the symptoms and signs of sJIA and exclude other mimickers; 
3) Know the current treatment options and understand the treatment to target 
approach; and 
4) Comprehensively care for patients with sJIA. 
 
3. Methods 
A literature review was conducted Jun. 1 2020 comprising all English articles 
from the 1970s onward in the MEDLINE/Pubmed database. Medical Subject 
Headings were used to search for JIA AND sJIA. Other supplemented words have 
been used, such as Still’s disease and systemic juvenile rheumatoid arthritis. All 
types of articles were reviewed, and determining usability for this review depended 
on the level of evidence, relation to the topic of interest and whether updated 
knowledge was considered. RTC and observational studies, such as cohorts, case 
series and case reports, were reviewed and included. The following organizational 
publications were reviewed so as to draw a review consensus on how to diagnose 
and treat sJIA: the American College of Rheumatology (ACR) guidelines, the 
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Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus, 
the Pediatric Rheumatology International Trials Organizations (PRINTO) and 
other paediatric rheumatology groups’ consensus. 
4. Epidemiology 
According to a recent systemic review, the prevalence of JIA was ranged from 
3.8 to 400/100,000, with an sJIA prevalence of 0 - 8.6/100,000 [8]. Systematic JIA 
comprises 10% - 20% of all JIA cases [9] [10]. However, these statistics vary geo- 
graphically. For instance, systemic JIA represented approximately 2.7% of a JIA 
cohort in Sweden, whereas it accounted for as many as 33% of JIA cases in 
Southeast Asia and even 50% in Japan [11] [12] [13] [14] [15]. The systemic 
JIA subtype proportion out of all JIA cases varied depending on how the data 
were collected and how many sites were involved; for example, single-centre 
studies in Saudi Arabia estimated that sJIA comprised 23% to 36% of all JIA 
cases, making it the most common subtype [12] [14]. However, sJIA 
represented only 17% in a population study of all paediatric rheumatology clin- 
ics in Oman, suggesting that it is the third most common subtype [15]. Although 
it can manifest at any age during childhood and adulthood, its incidence peaks 
between 1 and 5 years of age [10] [16]. It is the only subtype of JIA that has been 
shown to affect males and females in equal proportions [10] [16]. In addition, it 
affects all races, but the African Americans experience a higher burden of disease 
activity and persistent arthritis according to a recent CARRA cohort analysis 
[16]. 
5. Pathogenesis 
Systemic JIA exhibits more autoinflammatory than autoimmune features, which 
calls into question the precision of classifying sJIA under the JIA umbrella [17]. 
Its autoinflammatory features include innate immunity dysregulation, aberrant 
macrophage and neutrophil activation, and the subsequent release of cytokines 
and inflammatory proteins such as interleukin-1 (IL-1); interleukin-6 (IL-6) and 
interleukin-18 (IL-18); and S100A8, S100A9 and S100A12 [17]. 
Dissecting the roles of these cells, proteins and mechanisms to develop a sys- 
temic arthritis model is complex and not fully understood. Natural killer cells 
play a regulatory role in sJIA, as indicated by a study in mice that underwent the 
blockade of natural killer cell-activating receptors, causing an exaggerated and 
uncontrolled inflammatory response and an sJIA-like disease [18]. IL-18 cyto- 
kine is thought to have an upregulatory effect on interferon gamma, which leads 
to natural killer cell exhaustion and dysfunction and plays an essential role in the 
development of MAS [19] [20]. The changing paradigm in the recent history of 
sJIA treatment has been made possible through the successful use of medications 
that cause IL-1 and IL-6 receptor blockades, which have led to a substantial clin- 
ical and laboratory improvement in patients with sJIA, as well as reduced blood 
gene profile dysregulation [21] [22]. Other proposed mechanisms of sJIA devel- 
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opment include defective and insufficient IL-10 production by B-lymphocytes, 
which led to chronic inflammation status in already interferon-(IFNγ) deficient 
mice that have sJIA [23]. Persistent neutrophil activation occurs in active sJIA, 
as evidenced by increased levels of S100 8/9 protein levels from stimulated neu- 
trophils [24]. 
The lack of autoreactive T cells and autoantibodies in sJIA points to a very li- 
mited adaptive immune system role in the disease’s development [17] [25]. The 
adaptive immunity role in sJIA is apparent as recent studies have shown inter- 
sections with other forms of JIA associated with the major histocompatibility 
complex class II locus on chromosome 6 and another susceptibility locus on 
chromosome 1 [26] [27]. T cells, especially regulatory T cells (Tregs) and T ef- 
fector cells, are affected in sJIA cases and may play a role in its pathogenesis; 
Tregs, which express interleukin-17 A (IL-17A), are more commonly found in 
the blood of patients with an acute sJIA phase with high inflammatory markers 
than in patients with acute nonsystemic JIA and healthy controls [28]. Early in- 
itiation of IL-1 blockades apparently overrules and dampens IL-17 expression by 
Tregs [28]. 
Although the role of genetics in sJIA remains largely unclear and continues to 
evolve, recent studies using whole-exome sequencing have proven that some fa- 
milial cases of sJIA demonstrate a monogenic mutation in the LACC1 gene, 
which encodes for the laccase domain-containing enzyme at a region on chro- 
mosome 13 [17] [29]. LACC1 gene variants have a regulatory effect on TNF and 
IL-17 during inflammation [30]. In addition, specific polymorphisms in the cy- 
tokine regulation gene sequence may be associated with increased risk of sJIA, 
although additional studies have debated these findings [25]. 
6. Recognizing Clinical Manifestations of Systemic Juvenile 
Idiopathic Arthritis 
The ILAR defines sJIA as a quotidian fever with a 2-week duration, at least 3 
days of consecutive fever and the presence of arthritis in children before their 
16th birthday as cardinal features, along with one of the following: typical rash, 
hepatosplenomegaly, lymphadenopathy or serositis [1] (see Table 1). A significant 
proportion of patients do not have all of these criteria at the time of diagnosis [10] 
[16]. In a large North American cohort of 435 sJIA patients, 14% of those diag- 
nosed with sJIA did not meet the ILAR criteria because they lacked the specified 
quotidian fever or arthritis [16]. Demographic features and disease activity were 
similar between those who met ILAR criteria and those who did not [16]. 
Very recently, a newer classification of JIA was published, and the proposed sub- 
types of JIA were changed to six distinctive subtypes: early-onset Antinuclear anti- 
body-positive JIA, rheumatoid factor-positive JIA, enthesitis/spondylitis-related 
JIA, systemic arthritis, unclassified and others [31]. SJIA remained under JIA in 
the latest researchers’ effort, but some authors still call for a shift to a separate 
entity that falls under the category of autoinflammatory disorders [32]. The former 
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Table 1. ILAR diagnostic criteria for systemic juvenile idiopathic arthritis, Edmonton 
2001. Adapted from Petty, R., Southwood, T., Manners, P., Baum, J., Glass, D., Golden- 
berg, J., et al. (2001) International League of Associations for Rheumatology Classification 
of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. Journal of Rheuma- 
tology, 31, 390-392. 
Arthritis in any number of joints, together with a fever of at least 2 weeks’ duration that is 
documented to be daily (quotidian) for at least 3 days and is accompanied by one or 
more of the following: 
 Evanescent (nonfixed) rash 
 Generalized lymphadenopathy 
 Enlargement of liver or spleen 
 Serositis 
Exclusion criteria: 
1) Psoriasis in the index case or first-degree relative with psoriasis 
2) Arthritis in HLA-B27-positive males after the 6th birthday 
3) Ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory bowel disease, 
reactive arthritis, acute anterior uveitis or first-degree relative with one of those conditions 
4) Presence of immune globulin M rheumatoid factor on at least two occasions at least 3 months 
apart 
 
study also examined the consensus and acceptability of paediatric rheumatolo- 
gists to change the definition of systemic JIA to be comparable to a version of 
Yamaguchi’s criteria for AOSD with minor modifications [31]. The description 
of this newer definition is as follows: after excluding infection, malignancy, au- 
toimmune diseases and monogenic autoinflammatory diseases, a fever of un- 
known origin that is daily and documented for at least 3 consecutive days (with 
the quotidian pattern described below) and reoccurs over a duration of at least 2 
weeks with two major criteria or one major criterion and two minor criteria [31] 
(see Table 2). This newer adaptation, if it gets validated, will make arthritis an 
unnecessary criterion to diagnose sJIA [31]. 
Clinically, children with sJIA can be segregated into two phenotypes: systemic 
autoinflammatory with fever-predominate or arthritis-predominate features 
[33]. Cases of sJIA are defined as probable if arthritis has not yet developed de- 
spite all other cardinal or supportive clinical features [4] [34]. A case is defini- 
tively identified as sJIA if the patient develops arthritis and fever along with oth- 
er features [4] [34]. 
 Systemic Features 
Fever: Fever affects virtually all patients with sJIA and is the most common 
symptom [10]. The fever typically spikes daily and is therefore described as quo- 
tidian or double quotidian, defined as having one or two spikes of a temperature 
exceeding 39˚C, in a given day, followed by drops in temperature to normal le- 
vels or even below baseline [10]. A child with sJIA is usually unwell and ex- 
hausted, and rashes become more pronounced during fever episodes. In 
accordance with the definition, the fever must last for at least 2 weeks to justify a 
diagnosis of sJIA. In a Pennsylvania cohort, 51% of patients had a fever attributed 
to sJIA but did not meet the ILAR criteria for a typical fever [10]. In the CARRA 
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Table 2. Proposed definition of systemic juvenile idiopathic arthritis; First Step, 2019. 
Adapted from Martini, A., Ravelli, A., Avcin, T., Beresford, M.W., Burgos-Vargas, R., Cut- 
tica, R., et al. (2019) Toward New Classification Criteria for Juvenile Idiopathic Arthritis: 
First Steps, Pediatric Rheumatology International Trials Organization International Con- 
sensus. Journal of Rheumatology, 46, 190-197. 
Daily fever documented for at least 3 consecutive days with quotidian pattern reoccurring 
over at least 2 weeks with 2 major criteria or one major criterion and 2 minor criteria 
 
Major Criteria Minor Criteria 
• Evanescent erythematous rash 
•    Generalized lymph node enlargement and/or 
hepatomegaly and/or splenomegaly 
• 
Arthritis •    Serositis 
• Arthralgia lasting for 2 weeks or longer 
(in the absence of arthritis) 
• Leukocytosis (equal or more than 15,000/mm3) 
with neutrophilia 
 
cohort, only 25% of patients had a fever that met the baseline requirements for 
quotidian fever [16]. It is important to note that fevers that do not drop back to 
baseline or below might be a sign of severe infection or sJIA-complicated MAS 
[35]. 
Lymphatic and reticuloendothelial organ involvement: Another important 
feature is lymphadenopathy, which occurs in one-tenth to one-fourth of patients 
and is characterized by being generalized, non-tender, variable in size and with 
reactive hyperplasia when those nodes are checked histologically [4] [10]. Hepa- 
tomegaly, splenomegaly or a combination of the two comprises another element 
of the classification criteria, but they present in only 8% of patients [4] [10] [16]. 
Serositis: Serositis is another characteristic feature of sJIA found in approx- 
imately 7% of patients [10] [16]. Pericarditis, pericardial effusion, pleuritis and 
pleural effusion may also occur during the disease. Most serositis cases in the 
context of sJIA are asymptomatic and therefore tend to be discovered radiologi- 
cally, but a few patients may experience pericardial chest pain that becomes 
more prominent when lying supine, with pleuritic pain upon inhalation, cough 
and dyspnea or abdominal pain [4]. 
Sorethroat: Sore throat (i.e., pharyngitis) is a criterion of AOSD based on the 
1992 criteria by Yamaguchi and the 2002 criteria by Fautrel; it may be characte- 
ristic of sJIA presenting during adolescence but is not often reported among 
younger patients [4] [31]. 
 Dermatological Features 
The most common skin feature is an evanescent (fast to self-resolving) salmon 
coloured maculopapular rounded or oval-shaped rash that coincides with fever 
episodes and disappears after the patient’s temperature drops [4]. This type of 
skin eruption is part of the ILAR criteria for sJIA [1]. It occurs in approximately 
61% to 80% of patients and is commonly found on the trunk, upper thighs and 
arms or neck [10] [16]. A biopsy of this characteristic rash showed lymphocyt- 
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ic-predominate, neutrophilic or mixed infiltrate, along with remarkable expression 
of endothelial and epithelial markers [36] [37]. The kobener phenomena can be 
elicited in sJIA, but this is not pathognomonic because it can also occur in other 
diseases [4]. Pruritic urticaria and pustular rash are also occasionally described 
but are less common in sJIA [4]. 
 Arthropathy Features 
According to the ILAR’s 2001 criteria, the presence of arthritis is one prere- 
quisite for a diagnosis of sJIA. Arthritis can occur at the initial presentation, 
within the first 3 months or even later [10]. Joints subject to involvement in sJIA 
include wrists, knees, hip joints, ankles, the temporomandibular joint and cer- 
vical joints [4] [38] [39] [40]. Arthritis can be polyarticular, oligoarticular or, less 
frequently, monoarticular. In addition, it can persist for 2 years in more than 
one-third of patients [10] [16]. This is quite alarming because it can cause the 
destruction of joint structures, evidenced by erosion, narrow joint spaces and 
ankylosing [41]. Such destructive arthropathy may lead to serious limitations of 
joint movement and function, affect limb growth, require early joint replace- 
ment and even lead to micrognathia and cervical spine deformity, especially with 
delayed recognition of the disease [4]. Arthralgia may occur at the disease’s on- 
set but is still not included as part of the ILAR classification criteria for sJIA [16] 
[31]. In contrast, in the AOSD criteria, arthritis is not a necessary sign for diag- 
nosis [38]. It is important to note that MAS may complicate sJIA at the time of 
presentation and that a lack of arthritis is found more frequently in sJIA cases 
with concomitant MAS than active sJIA alone [42]. 
  Other Atypical Manifestations of Systemic Juvenile Idiopathic Arthritis 
Interstitial lung diseases are reported rarely [43] [44]. Patients may present 
with cough, hypoxia and clubbing, which are associated with a high frequency of 
IL-6 inhibitor reactions [43] [44]. Alveolar proteinosis and endogenous lipoid 
pneumonia are the most common pathological findings upon lung biopsy [43] 
[44]. Radiologically, the patterns found include diffuse ground-glass opacities, 
subpleural reticulation, interlobular septal thickening and lymphadenopathy 
[43] [44]. Pulmonary hypertension has also been rarely documented [4]. 
Some children may present with Kawasaki disease (KD) manifestations with 
or without coronary artery aneurysm, and these cases tend to be unresponsive to 
typical management with intravenous immunoglobulin and aspirin [45] [46]. In 
a U.S. database study of more than 6000 KD cases, 0.2% were presumed to have 
KD and then diagnosed with sJIA. MAS is more associated with sJIA cases than 
KD cases (30% with sJIA with KD versus 0.3% with KD only) [46]. The fre- 
quency of coronary artery abnormalities was not statistically different between 
the cases that turned out to be sJIA with KD versus KD-only cases [46]. Intra- 
cardiac mass and valvulitis have been rarely reported with sJIA [47]. 
Aseptic meningitis and uveitis have been infrequently documented with sJIA 
[4]. Proteinuria and secondary amyloidosis have been described in AODS, but 
rarely in sJIA in the literature, and may benefit from biologic treatment [48] 
[49]. Renal amyloidosis complications appear more frequently in patients with 
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sJIA who carry familial Mediterranean fever gene mutations [50]. 
 Macrophage Activation Syndrome 
MAS is a secondary form of hemophagocytic lymphohistocytosis (HLH) syn- 
drome associated with autoimmune and autoinflammatory diseases, classically 
with sJIA, that leads to bone marrow failure and pancytopenia [51] [52]. As its 
name suggests, it results from the engulfment of blood cells by activated macro- 
phages (histiocytes) and persistent T lymphocytes and macrophage activation in 
the reticuloendothelial organs, leading to cytokine overproduction [53] [54]. In 
animal models, MAS can be induced by repeated toll-like receptor-9 (TLR-9) 
stimulation in mice with normal genetic makeups [55]. Clinical manifestations 
include high fever, being unwell and splenomegaly, as well as signs of bone 
marrow failure such as petechiae, bruises and pallor [51] [52]. Extreme hyper- 
ferritinemia is a significant finding in 95% of cases [56]. Hypertriglyceridemia, 
low serum fibrinogen and declining erythrocyte sedimentation rate (ESR) are 
distinguishing laboratory features of MAS [51] [52]. 
Classification criteria were developed to assist physicians in detecting MAS in 
patients with sJIA in 2016; they suggest that MAS should be diagnosed when a 
child with a confirmed or presumptive diagnosis of sJIA is febrile and has 
hyperferritinemia (more than 684 ng/ml), as well as two of the following four 
abnormalities: low platelets (less than or equal to 181 × 109/L), high aspartate 
aminotransferase level (AST); (greater than 48 units/L), high triglycerides (more 
than 156 mg/dl) or low fibrinogen (less than or equal to 360 mg/dl) [57] These 
2016 MAS classification criteria, although they are not considered diagnostic, 
appear to detect more cases of MAS, appear to be more sensitive and more in- 
clusive and have a lower threshold to diagnose MAS in sJIA than the previously 
used metrics, such as the primary HLH 2004 criteria [57] [58]. A retrospective 
study that compared the available classifications found that MAS that compli- 
cated sJIA was not diagnosed at all when using HLH-2004 criteria, but the 2016 
classification criteria detected MAS in 11% of patients [59]. 
A recent study reported that a high ferritin-to-ESR ratio can be used to diffe- 
rentiate sJIA complicated by MAS from only an active phase of sJIA, with ac- 
ceptable sensitivity and specificity of 82% and 78%, respectively [56]. Recently, 
MAS/sJIA (MS) scoring, another diagnostic scoring system used to differentiate 
sJIA complicated by MAS, was introduced in 2019 and validated with a sensitiv- 
ity of 85% and a specificity of 95% [42] [60]. The MS scoring system is based on 
the following components: presence of central nervous system manifestation, 
presences of hemorrhagic manifestation, lack of active arthritis, level of platelets, 
fibrinogen, ferritin and lactate dehydrogenase (LDH) [42]. 
MAS can occur at the onset of the disease or during its course even if the pa- 
tient is receiving treatment [35] [61]. The prevalence of MAS in patients who 
had bone marrow aspirate and a diagnosis of sJIA was around 13% in a retros- 
pective cohort [62]. Moreover, there is an increased awareness that MAS may 
occur in subclinical or partial form in almost one-third of patients with sJIA, 
which explains the low laboratory threshold for 2016 MAS classification criteria 
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[63]. The concern has also been raised that biologics might mask MAS; patients 
with sJIA who were treated with canakinumab and tocilizumab tended to devel- 
op MAS with lower ferritin levels than the historical cohort. In addition, tocili- 
zumab-treated patients tended to be less febrile, but with lower levels of platelets 
and fibrinogen and higher AST levels [61]. 
7. Laboratory Findings 
At present, no single test can confirm a sJIA diagnosis. Increased acute phase 
reactant is a hallmark, as are leukocytosis, thrombocytosis, increased ESR and 
C-reactive protein (CRP) level in around 85% - 95% of cases [4] [64]. 
Anaemia is another common finding [4] [64]. Moreover, elevated  ferritin 
above 500 ng/ml occurs in approximately 70% of cases, and increased AST or ala- 
nine aminotransaminases (ALT) occurs in one-fourth of cases [64]. Extremely 
high ferritin in the presence of low ESR increases the possibility of MAS [56]. 
Extremely high platelet levels (above 1000 × 109/litre) should increase the suspi- 
cion of KD [46]. Antinuclear antibodies (ANA) and the rheumatoid factor are 
typically negative in sJIA [4]. 
Other laboratory tests that might detect complications or exclude other mi- 
mickers include the following: microbiological cultures and viral panels, peri- 
pheral blood smears, bone marrow aspiration, biochemical panel for MAS (LFT, 
Triglycerides, LDH and coagulation profile including fibrinogen and D-diamer), 
genetic studies, echocardiography and chest X-ray [4] [64]. Phagocyte-specific 
protein S100, if available, is a good biomarker to differentiate sJIA from other 
febrile illnesses [34] [65]. Procalcitonin is an acute phase reactant, and data are 
not adequate to determine its role in sJIA [34]. 
8. Differential Diagnoses of sJIA 
The diagnosis of sJIA is largely clinical, so it is necessary to proceed by first ex- 
cluding other serious systemic illnesses, such as infection and malignancy, before 
commencing the mainstay treatment [64]. Malignancies, especially leukaemia 
and lymphoma, can mimic sJIA and its concomitant MAS [64]. A careful review 
of symptoms, peripheral blood smears and even bone marrow aspirate or lymph 
node samples as indicated on a case-by-case basis, are extremely helpful when 
seeking to exclude malignancy. Infections that may cause viral exanthema, such 
as measles, parvovirus, influenza, parainfluenza, herpes virus 6, Epstein-Barr vi- 
rus and cytomegalovirus, must be ruled out [4] [64]. Viral exanthem tends to be 
persistent and not fleeting like the evanescent-rash associated with sJIA [4] [64]. 
Differential diagnoses of arthritis, such as septic arthritis, post-infectious arthri- 
tis, rheumatic fever, transient synovitis, Lyme disease and brucellosis, should be 
entertained when a child presents with fever and arthritis, as indicated by the 
case [64]. Other autoimmune and inflammatory conditions that may mimic sJIA 
to a great extent include systemic lupus erythematous (SLE), KD and other vas- 
culitic diseases, periodic fever syndromes and even other causes of HLH (famili- 
al or acquired) or immunodeficiencies [64] [66] (see Table 3). 
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Table 3. Mimickers of systemic juvenile idiopathic arthritis. 
Mimickers of systemic juvenile 






 Deep-seated infections: abscesses or osteomyelitis 
 Prolonged fever causes: tuberculosis, brucellosis 
 Post-infectious arthritis: streptococci 
 Viruses: EBV, CMV, parvovirus, measles, HIV 
Malignancy Leukemia or lymphoma 
Autoimmune disease SLE or polyarticular JIA with systemic manifestations 
Vasculitis KD or polyarteritis nodosa 
Autoinflammatory periodic fever diseases TNF receptor periodic fever 
Immunodeficiencies Especially those that may present with HLH 
9. Treatment Outline of Systemic Juvenile Idiopathic 
Arthritis 
The aims of treatment are suppression of the inflammatory process; prevention 
of joint damage; controlling articular and systemic symptoms; optimizing func- 
tion; supporting the growth, motor and social development of affected children; 
and minimizing medication toxicity and side effects [6]. Treating to target is an 
approach that is well supported by paediatric rheumatology guidelines and de- 
fined by reaching clinical remission or low disease activity at minimum [6]. The 
treatment should be individualized to the patient’s and the disease’s characteris- 
tics and agreed upon by the child and parents. Evaluating the severity including 
the persistence of systemic manifestations, degree of joint involvement, critical 
organ involvement, history of relapses, response to treatment and presence of 
MAS is a crucial part of providing the most suitable targeted treatment regimen 
[6]. 
The immediate goal of treatment is to quickly decrease the fever within a 
week, as well as alleviate serious complications, such as active pericarditis and 
pleuritis and severe MAS, to control other articular and non-articular manifesta- 
tions during the first 3 months of the disease, with a minimum improvement of 
50% from the start of the therapy [6] [34] [67]. Clinical disease inactivity or low 
disease activity should be reached by 6 months [6] [34] [67]. A tighter time 
frame is needed in the management of sJIA in comparison to other subtypes of 
JIA because of the serious complications of systemic manifestations, such as 
MAS, and evidence of earlier inflammatory control will lead to better prognosis 
[6]. 
Although corticosteroids have been considered a mainstay treatment for many 
decades, anakinra was also proven effective and relatively safe as initial mono- 
therapy in longitudinal observational studies [5] [34] [68]. Nonsteroidal an- ti-
inflammatory drugs (NSAIDs) and methotrexate are still in use, particularly to 
control mild symptoms initially and to manage arthritic manifestations, respec- 
tively, given their well-known safety profiles and cost [34] [68]. 
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 Corticosteroids 
Corticosteroids are considered the mainstay in the management of mod- 
erate-to-severe symptoms of sJIA [69]. If a patient is severely affected, intraven- 
ous pulse therapy with methylprednisolone (30 mg/kg/day for 1 - 3 days) 
should be initiated [68]. Oral corticosteroids can be started using prednisolone 
or prednisone at doses of 1 mg/kg/day up to 2 mg/kg/day and then reassessed 
weekly or monthly depending on the response and disease activity [68]. All ef- 
forts should be made to decrease the dose and duration of corticosteroids to mi- 
nimize long-term toxicity by tapering the oral corticosteroids to 0.5 mg/kg/day 
and then weaning off of it as soon as remission or low disease activity is reached 
[68]. If clinical status worsens or is unchanged, despite optimization of the oral 
corticosteroids to a 2-mg/kg/dose in the initial few weeks, additional therapy 
with biologics should be added [68]. 
 Biological  DMARDs 
Many experts believe that earlier modulation and suppression of cytokine re- 
lease might potentially decrease the long-term impact of the disease, signifying 
the notion that a “window of opportunity” exists and leading to the successful 
management of such a disease [70]. Therefore, treatment is recommended as 
early as possible to achieve early control of inflammation and cytokine storm 
and subsequently avoidance of chronic arthritis [6]. It is also well known that a 
persistently active disease that involves persistent fever and requires corticoste- 
roids for more than 6 months has a poor functional outcome [71] [72]. 
1) IL1 Inhibitors: 
Since Pascual’s 2005 report on IL-1’s role in the pathogenesis of systemic JIA 
and its clinical effect, the usage of IL-1 inhibitors has increased [73] [74] [75]. 
Anakinra and canakinumab are the most-used medications from this category 
and have received approval from most drug authorities around the world [7]. 
Riloncept is an investigational drug [7] (see Table 4). 
Using Anakinra: In 2011, a double-blinded randomized control study called 
the ANAJIS trial was published regarding the efficacy of daily subcutaneous 
(SC) anakinra in 12 sJIA patients allocated to each arm with persistently active 
disease despite corticosteroid use [21]. The study proved the short-term effi- 
cacy and safety of anakinra, with almost 92%, 58% and 42% of patients who 
received anakinra showing statistically significant resolution of fever and im- 
provement of arthritis using the JIA-American College of Rheumatology Pedia- 
tric’s 30 response criteria (ACRpedia 30), ACRpedia 50 and ACRpedia 70, re- 
spectively, compared to 58%, 0% and 0% of participants in the placebo group 
[21]. Ter Haar prospectively studied 42 patients with newly diagnosed sJIA who 
were treated with anakinra first as monotherapy and she followed them up for 5 
years; three-quarters of the cohort showed inactive disease at the 1-year mark, 
whereas almost all showed inactive disease at 5 years [5]. One-third of the cohort 
needed corticosteroids during the treatment [5]. Furthermore, excellent clinical 
response to anakinra at 1 year was more noticed in patients with the following 
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Table 4. A summary of currently used biologics for systemic JIA. 
Drug and studies 
included 
in this summary 
 
Mode of action 
 
Effectiveness as per studies 
Dosage and route 
included in this summary 
 
An RTC study recruited sJIA patients who had 
uncontrolled JIA despite NSAIDs and 
corticosteroids usage; and received TCZ 








 By 3 months, 85% of sJIA patients who received 
TCZ reached ACR30 response and no fever, 
71% reached ACR70 response and 37% 
reached ACR90 response compared to 
less than 25% who become afebrile and has 
ACR 30 in the placebo group [22] 
 Three-quarters of patients with sJIA 
treated with TCZ had higher height 
velocities (6.6 cm/year) [78] 
 Intravenous route 
 Weight < 30 kg: 12 mg/kg/dose 
 Weight > 30 kg: 8 mg/kg/dose 





















1) RTC study was done on sJIA pateints who had 
persist ently active disease despite CS or NSAIDs 
[21] 
 By one month, 92% of patients receiving ANK 
reached ACR30 response and no fever, 58% 
reached ACR50 response and 42% reached ACR 
70 response [21] 
 Median time to achieve remission was 33 days 
 76% of patients of ANK users had inactive 
disease at 1 year and 52% of ANK users had 
inactive disease while on medication [5] 
2) A prospective cohort studied newly diagnosed 
sJIA pateints who treated with ANK as initial 
treatment [5]: 
 At five-year-mark, 96% of patients had inactive 
disease and 76% of patients had inactive disease 







 Subcutaneous route 
 2 mg/kg/day 















Rilonacept [84] [85] 














of three fused parts 
Acts against 
IL-1 alpha 
and IL-1 beta 
An RTC included sJIA patients with active 
disease, could be in low dose daily CS or 
NSAIDs, included 190 patients: 
 At 15 days, 84% of CAN receivers reached 
ACR30 response 
 At the open-label part, 1/3 attained inactive 
disease, and 73% reached ACR 50 response 
 In the withdrawal phase, relative risk reduction 
of flares was 64% lower in the CAN group 
 33% of patients received CAN discontinued CS 
 At 4 weeks, 60% and 40% of the 
rilonacept-treated group had ACR50 response 
and ACR70 response, versus 30% 
and 12% of those in the placebo group respec- 
tively. 
 Time to respond was shorter in the 
rilonacept-treated group 
 The CS has been weaned off in most of 




 Subcutaneous route 
 4 mg/kg/dose Max dose: 300 mg 








 Should be given weekly 
 4.4 mg/kg loading dose and 
then 2.2 mg/kg weekly doses 
 
Abbreviations used in Table 4: ANK: anakinra, CAN: canakunimab, CS: corticosteriod, TCZ: tocilizumab. 
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clinical profile: shorter disease duration, presence of a higher degree of systemic 
manifestations, higher ferritin and neutrophil count and lower active joints at 
the start and early complete response to anakinra at 1 month [72] [73] [74]. On 
the basis of the growing evidence on anakinra’s effectiveness and safety profile, 
the relative ease of administration and the feasibility of using the medication at 
home, anakinra has become the first option to treat sJIA, when it is affordable, to 
avoid corticosteroids and their long-term complications and to achieve early 
induction of remission [2] [5] [70]. 
Many studies showed that a longer duration from the onset to diagnosis and 
treatment with biologics tends to lead to poorer treatment response [72]. In a 
retrospective study, the only difference between responders to anakinra and 
non-responders was the time between the onset of disease and the start of ana- 
kinra treatment, with a mean of around 2 months in the responder groups ver- 
sus a delay of 2 years from the start anakinra in the non-responder groups [73]. 
Side effects of anakinra include post-injection pain and injection site erythe- 
ma, thrombocytopenia, infections including laryngitis, bronchitis, atypical 
pneumonia, varicella, herpes simplex, cutaneous infection, gastroenteritis and 
UTI [2] [5] [21]. Refer to Table 5 for a review of side effects of common medica- 
tions have been used to treat sJIA. 
Using Canakinumab: Canakinumab is a selective human anti-interleukin-1β 
monoclonal antibody. Canakinumab has shown efficacy in treatment of active 
sJIA, with a significant portion of patients reducing their steroid use. The effect is 
fairly sustainable, but medication cessation is common [76] [77]. A double-blinded 
phase of the randomized clinical trial led by Ruperto showed that 81%, 79% and 
67% of patients in the canakinumab arm achieved adapted ACR30, adapted 
ACR50 and adapted ACR70, respectively, at the 1-month mark, versus 10%, 5% 
and 2% of patients in the placebo group [76]. A longitudinal study showed that 
half of patients unfortunately discontinued medication, principally due to inef- 
ficacy [77]. 
Forty out of 100 patients per year reported side effects, including flare of sJIA, 
MAS and infections [61] [76] [77]. Increased LFT was occasionally reported 
(0.63 out of 100 patients per year) [76] [77]. Refer to Table 5 for a review of side 
effects of common medications have been used to treat sJIA. 
2) IL-6 Inhibitors and Use of Tocilizumab (TCZ): 
TCZ is an anti-interleukin-6 receptor antibody. It is proven to be effective in 
treating active sJIA uncontrolled with first-line corticosteroids or anakinra. A 
randomized control study with a 12-week double-blinded phase recruited 112 
sJIA patients who had uncontrolled JIA despite NSAID and corticosteroid usage, 
and they received TCZ or a placebo [22]. By 3 months, 90% and 85% of sJIA pa- 
tients had reached an ACR30 and ACR50 response and had no fever, compared 
to only 24% and 10% of patients in the placebo group [22]. Fever and rash and 
laboratory abnormalities (anaemia, thrombocytosis and hyperferritinemia) also 
significantly decreased in the TCZ group. In the open-label phase at 52 weeks, 
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Table 5. Medication side effects. 



























 MTX [85] [111] 












(ankinra and canakinumab) 



















 Skin: stria and acne 
 Eyes: cataract and 
glaucoma 
 Hypothalamic pituitary 
adrenal axis dysfunction 
MTX 
 GI symptoms and gastritis 
 Mucocutenous 
manifestations such as rash, 
mouth ulcers or alopecia 
 Elevated transaminases 
 Pneumonitis 






 GI symptoms: nausea, 
vomiting, diarrhea 
 Elevated transaminases 
 Headaches, tremor, seizure 
 Gingival hyperplasia 
 Hypertrichosis 
 High lipid profile 
 Hypersensitivity reaction 
and can cause serious 
anaphylaxis 
 Flare up of a LTBI 
 Infections (herpes zoster, 
salmonella, coccidiose) 
 Increase liver enzymes 
 Thrombocytopenia 
 Infections such as URTI 
and herpes reactivation 
 Neutropenia (0.77 
incident/patient-year) 
 Hepatic toxicity 
(3.33 incident/patient-year) 
Symptoms check 
Periodic LFT and RFT 
 
 
 Periodic fasting serum glucose 
test 
 Regular blood pressure 
measurement with each visit 
 Annual lateral lumbar spine 
X-rays and DEXA scan if 
patient continues on CS 
more than one year 
 Yearly eye exam by 
ophthalmologist for slit lamp 








 Baseline and periodic CBC, 
ESR, LFT, RFT, urinalysis 
 Live vaccines are 
contraindicated 
 Baseline varicella titres and 
MMR before treatment 
Cyclosporine 
 Baseline and periodic creati- 
nine, urea and electrolytes tests 
 Lipid profile 















Periodic CBC, LFT, RFT 
and coagulation profile 
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59% of participants had reached ACR90 and fever resolution, 48% had reached 
no active joints and 52% had discontinued corticosteroids [22]. 
The longitudinal open-label study following up with the above cohort showed 
the catch-up growth of children who used TCZ. At least three-quarters of pa- 
tients with sJIA treated with TCZ had greater height velocities (6.6 cm/year) 
[78]. There is no head-to-head comparison between anakinra and TCZ. 
An earlier 6-week open-label study in 2008 also showed the more impressive 
efficacy of TCZ in children with sJIA, with 90% reaching ACR pedia 30 and 86% 
reaching ACR Pedi 50 [79]. The second part of the study was a double-blinded 
randomized placebo-controlled study conducted for 12 weeks until withdrawal 
for rescue, with an open-label extension phase lasting 48 weeks. The results at 48 
weeks were remarkable, with more than 90% reaching ACR pedi 70 [79]. 
TCZ has been approved for children older than 2 years [80]. A Phase 1 trial 
for children younger than 2 years was recently published and indicated that the 
pharmacokinetics and pharmacodynamics of the drug were comparable with 
those of the older group (>2 years), but the trial pointed to a higher frequency of 
serious hypersensitivity in the younger group (27% versus 2.6%) [80]. 
Neutropenia of grade 3 and above appeared to occur in 25% of cases. Infec- 
tions such as varicella, herpes, lower airway infections and gastroenteritis are 
documented during TCZ treatment and do not appear in association with neu- 
tropenia [22] [81]. Increased ALT and AST levels are also a frequent side effect 
[22]. Severe hypersensitivity and MAS are reported and might cause withdrawal 
from treatment [22] [43] [61]. Refer to Table 5 for a review of side effects of 
common medications has been used to treat sJIA. 
Examples of investigational IL-6 inhibitors that have been used are IV siltux- 
imab and sarilumab for refractory sJIA [82]. An ongoing clinical trial examined 
the pharmacokinetics of sarilumab, an IL-6 receptor monoclonal antibody [83]. 
Other Modalities of Treatment: 
 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
NSAIDs are initiated early in the course for newly diagnosed sJIA, continue 
until diagnostic investigation is complete and may alleviate mild arthralgia and 
arthritis. An NSAID trial could be useful for cases characterized by the absence 
of severe systemic symptoms and no signs of MAS, according to a 14-year re- 
trospective chart review study in an Italian tertiary hospital that showed that 
one-fourth of patients reached the status of disease inactivity in around 7 weeks 
(median) while they were on NSAIDs monotherapy [84]. Those patients who 
were responsive to NSAIDs monotherapy were younger at the time of the pres- 
entation and had lower joint counts and lower initial CRP levels in the above- 
mentioned study [84]. 
Ibuprofen, naproxen or indomethacin can be used. If symptoms and inflam- 
mation are not under control or proceed to escalate, upgrading treatment to in- 
clude steroids or biologics is warranted. 
 Conventional  DMARDs 
Methotrexate used to be most commonly utilized as a steroid-sparing medi- 
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cation s for patients with severe symptoms and early MAS [85]. However, its use 
has been declining because of its limited effectiveness [85]. It is still considered 
effective for persistent articular symptoms in combination with steroid or bi- 
ologic line therapy [34] [68]. A methotrexate-only regimen is unlikely to lead to 
clinical remission and is inappropriate therapy for the hyperinflammatory phase 
[86]. 
Cyclosporine is another agent indicated for refractory or chronically active 
sJIA [9] [87]. A recent observational study showed that cyclosporine led to 
favourable outcomes in 75% of refractory steroid-dependent sJIA cases in areas 
where the availability of biologics was limited and too expensive to cover the cost 
[88]. 
Other Medication under Investigation: 
 Jak inhibitors usage has increased lately in cases with evident inflammation 
[89]. A few case reports have shown positive results for patients with refrac- 
tory sJIA [90] [91]. A clinical trial investigating the efficacy and safety of to- 
facitinib is ongoing [92]. 
 Tacrolimus was studied retrospectively in a small cohort study of six Chinese 
children with sJIA. Results showed that tacrolimus use led to a decrease of 
corticosteroid use at 6 months and 12 months [93]. IL-6 expression reduction 
was postulated as the tacrolimus mechanism of action to treat sJIA [93]. No 
randomized controlled trial has studied the efficacy of tacrolimus in sJIA. 
10. Common Questions in the Management of sJIA 
Among biologic and non-biologic treatment options, which treatment 
should preferably be started first for a patient suspected to have sJIA? 
Based on the available guidelines, the initial treatment for patients with sys- 
temic features with or without arthritis should be either a high-dose steroid 
(whether an IV pulse steroid or oral prednisolone at 1.5 - 2 mg/kg/day with a 
tapering schedule) or anakinra monotherapy. The aim after starting medication 
in the first week is fever resolution and reduction of CRP by 50% [6] [34] [68]. 
Daily to weekly assessment is crucial in the first month until disappearance of 
inflammation. TCZ or canakinumab has not yet been recommended for use as 
an initial monotherapy as per the latest guidelines, due to the lack of studies in 
this scope [34]. In contrast, a CARRA case-based survey in 2013 pointed out that 
some paediatric rheumatologists may opt to use TCZ as one of the initial treat- 
ment plans in the first 9 months with or without steroids [68]. 
What is the next management step if there is evidence of an inadequate 
response to the initial treatment regimen, such as corticosteroids or anaki- 
nra? 
If an inadequate response is confronted, repeating the pulse steroids, increas- 
ing the dose of steroids or anakinra or adding steroids or anakinra to the initial 
regimen is highly recommended to attain better disease control [34]. If the pa- 
tient develops recurrent flares, persistent systemic manifestations or dependency 
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on steroids, then it is advisable to add IL-6 or IL-1 inhibitors, if the patient is ex- 
clusively treated with steroids, or to increase or change of the biologics, if the pa- 
tient is already on one of the biologics [34]. 
Physicians should frequently assess the disease activity and ideally aim to 
reach clinically inactive disease [6]. The definition of inactive disease typically 
involves resolution of systemic manifestations (fever and rash), arthritis and la- 
boratory abnormalities such as high CRP level, anaemia, thrombocytosis, hyper- 
ferritinemia and any other complications (e.g., MAS) [94] [95]. 
How should sJIA with predominant arthritis treated? 
Based on ACR guidelines, initial treatment for those with predominant arthri- 
tis varies between usage of NSAIDs for 1 - 2 months, of intraarticular steroids if 
patients have very few joints involved or even of add-on methotrexate or leflu- 
nomide if there is a higher number of joint counts [96]. In the case of failure of 
these treatments or inadequate response, anakinra is recommended [96]. In the 
case of no response, abatacept or TCZ is recommended [96]. 
The latest German guideline suggests starting with a glucocorticoid and uti- 
lizing biologics such as anakinra [34]. If the response to anakinra is inade- 
quate, TCZ or canakinumab is recommended [34]. At 4 weeks’ time, arthritis 
is expected to resolve by at least 50% as an indicator of treatment success [34]. 
Third-line treatment with TNF inhibitors such as etanercept or adalimumab, 
abatacept or MTX can be added if first- and second-line treatment has failed to 
control the arthritis-predominant sJIA [34]. Intraarticular glucocorticoids may 
be used [34]. 
What is the role of combining different biologics? 
Combination of biologics is discouraged [34]. If a biologic treatment proves 
unsuccessful or leads to serious adverse effects, the physician should stop the 
treatment and start using the another biologic, with no washout period needed 
[34]. 
How should one follow-up on patients with sJIA who are on medication? 
Assessment and management of patients with sJIA might involve hospitaliza- 
tion, either to confirm the diagnosis and exclude other serious mimickers or un- 
til systemic manifestations (especially fever), critical severe organ involvement 
(pericarditis, or lung involvement, etc.) or MAS have lessened [9]. Weekly as- 
sessment might be suitable for active sJIA with high disease activity, and then 
assessments monthly to every three months for moderate to low disease activity 
to adjust medication accordingly (see Figure 1). 
The targets of treatment are the following: 
 Within one week of treatment commencement, fever resolution and 50% re- 
duction of CRP level are expected [6] [34]. 
 Four weeks after the start of treatment, 50% improvement of disease activity 
is expected, such that there will be either a JADAS-10 score of 5.4 at maxi- 
mum or at least 50% improvement and reduction of the following measures: 
physician global disease activity or active inflamed joint counts [34]. 
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Figure 1. Treatment goals for systemic juvenile idiopathic arthritis in stepwise fashion. 
Figure is adapted from: Hinze, C.H., Holzinger, D., Lainka, E., Haas, J.P., Speth, F., Kalli- 
nich, T., et al. (2018) Practice and Consensus-Based Strategies in Diagnosing and Man- 
aging Systemic Juvenile Idiopathic Arthritis in Germany. Pediatric Rheumatology, 16. 
 
 Clinically inactive disease or low disease activity should be reached while the 
patient is on treatment at 3 - 6 months after commencing it [6] [34]. 
 The best clinical outcome would be clinical remission is reached within 6 
months or 12 months at maximum while the patient is on no glucocorticoids, 
on or off other medication. 
Disease activity has been quantified by different measures for research pur- 
poses to ensure objectivity. Examples of these scales are the juvenile idiopathic 
arthritis JADAS-10, the modified systemic JADAS score or the physician global 
score. The JADAS-10 score includes: 1) the physician global assessment (range 0 
- 10), 2) the patient’s or parent’s global assessment (range 0 - 10), 3) the active 
joint count (range 0 - 10) and 4) the normalized erythrocyte sedimentation rate 
after 1 h (score = [observed rate − 20]/100) or C-reactive protein level (score = 
CRP in mg/l − 10]/100) [97]. 
Disease inactivity is defined as per modified Wallace criteria as the absence of 
active arthritis, morning stiffness and systemic features (fever/rash/serositis/ 
splenomegaly/lymphadenopathy due to JIA); a physician global assessment that 
indicates no disease activity (<10 on a scale of 0 - 100); and normalization of 
ESR (<20 mm/hour) and CRP levels (<10 mg/litre) [94] [95]. 
When should the patient be weaned off of medication? 
Within the first 3 to 6 months, the aim is to reach inactive disease to plan the 
weaning off of medication to achieve clinical remission [34]. A recent survey was 
conducted and showed that most rheumatologist participants would agree with 
Wallace criteria as the matrix to define clinically inactive disease in sJIA. Taper- 
ing medications should be decided on the basis of patients reaching clinical re- 
mission on medication (CRM), defined as 3 to 6 consecutive months or more of 
inactive disease while on medication [98]. However, a few rheumatologists un- 
derstandably would like a more stringent approach, with 1 year of clinical remis- 
sion while pateints are on medication [98]. It is advisable to taper steroids early 
and first because of their side effects within the first 6 months, even before pa- 
tients reach full CRM [34] [98]. 
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How should patients be weaned off the medications used to treat sJIA? 
 Steroids should be tapered gradually from a high dose to lower doses very 
early, within 1 - 3 weeks, if systemic inflammatory symptoms have subsided 
[98]. Then, weaning off of a steroid gradually should be planned within the 
first 6 months [34]. 
 Past failure to taper, intolerance or toxicity of medications, previous flares 
and MAS were important factors in surveyed rheumatologists’ decisions on 
when to taper medications [98]. 
 Weaning patients off of anakinra is usually accomplished by using an alter- 
nate-day regimen, which means using it every other day for a month and 
then stopping its use if the child continues to be in remission clinically and 
biochemically [5] [21]. The length of the withdrawal period varies substan- 
tially, from a month to more than 6 months [98]. 
 TCZ and canakinumab are usually tapered by lengthening the interval be- 
tween the doses over period of 2 - 6 months or longer, rather than by de- 
creasing the dose [22] [77] [98]. 
 Closer follow-up with clinical and laboratory reassessment is needed after 
medication withdrawal [34] [98]. 
11. Prognosis and Fatality 
The mortality due to sJIA is reported and related to the following causes: MAS, 
infection, treatment-related complications and disease-related complications 
(such as pulmonary interstitial lung disease, alveolar proteinosis, myocarditis, 
etc.) or malignancy [99] [100] [101]. 
The data in the pre-biologic era showed that the standardized mortality rate of 
systemic JIA reached a level of 1.8/1000, based on an American registry [99]. In 
the modern era, the mortality rate and standardized mortality rate of sJIA have 
been higher than those of non-systemic JIA. In 2014, it was reported that the 
mortality rate due to sJIA reached 3.9/1000 person-years, and the standardized 
mortality rate reached 8 per 1000 of the population, based on a UK cohort [100]. 
There were five deaths out of 196 sJIA cases in a later cohort, and the reported 
causes of death were infection, complication of stem transplant, MAS, asthma 
and accidental overdose [100]. MAS alone complicates 10% to 36% of sJIA cases, 
and mortality due to MAS might reach up to 20% [51] [101] [102] [103] [104]. 
Occurrence of lung disease with sJIA is quite rare, but having sJIA with lung 
disease leads to a mortality of almost 159/1000 person-years [44]. 
The disease has three well-described patterns in longitudinal cohort studies, 
especially true for the pre-biologic era: 1) the persistent disease course (51%), 
defined as ongoing systemic features and/or arthritis, which leads to a higher 
proportion of patients with functional disabilities compared to the proportion of 
monophasic patients; 2) the monophasic course (42.2%), defined as one episode 
of systemic features and arthritis, which may last for a maximum of 24 months 
but are followed by complete recovery, cessation of medication and no recur- 
rence; and 3) the polyphasic course, comprising 6.7% of patients and defined as 
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episodes of active systemic features and arthritis with remission periods in be- 
tween them [105]. 
The most recent studies have shown a positive outcome of sJIA, even better 
than that of other forms of JIA. The short-term outcomes were investigated in 
an Australian inception JIA cohort study that targeted the first year of diagnosis, 
using a joint count of zero as an indicator of inactive disease [106]. At the one-
year mark from the diagnosis, this study showed that 30% of sJIA patients had 
inactive arthritis with no medication, 40% had inactive arthritis while on 
medication and 30% had active arthritis while not on medication [106]. In 
another study in Turkey, almost 48% of patients reached remission while off 
medication [101]. In a longitudinal follow-up study based on a Nordic popula- 
tion of patients with JIA, the outcome was described as favourable for sJIA, with 
53.8% of sJIA patients achieving remission while off medication, 8% having re- 
mission while on medication and 22% having active disease 18 years after dis- 
ease onset [107]. In a very recent Canadian-based study (ReCCH-OUT), 71% of 
patients with sJIA achieved remission with no medication, the highest 
favourable result out of all JIA patients [108]. 
12. Comprehensive Care and Disease’s Complications 
There are other important issues that should be considered in parallel with me- 
dication usage to optimize sJIA care, such as the following: 
1) Immunization record review and completion 
2) Clearance from and further risk reduction of infections 
3) Monitoring of growth, development and childhood well-being 
1) Immunization Record Review and Completion 
Immunization records should be checked and completed for each sJIA pa- 
tient. If possible, all vaccines should be completed before starting an immuno- 
suppressant because live attenuated vaccines are contraindicated in children re- 
ceiving an immunosuppressant due to the risk of having a vaccine-type infection 
[109] [110] [111]. Moreover, these vaccines may need a few weeks to build up 
the expected vaccine protection and immunity, but an immunosuppressant may 
decrease the immune response to the vaccines. The physician should weigh the 
benefit against the risk of commencing corticosteroids or DMARDs before com- 
pleting immunization of a child. Annual influenza vaccine administration is 
recommended for children and household members [112]. It is highly important 
to request that all household residents be completely vaccinated if there are no 
contraindications [109]. 
2) Infections and Immunosuppression Risk 
Latent tuberculosis infection (LTBI) should be ruled out before the start of 
immunosuppressant use [6] [113]. Verifying the exposure history to a source TB 
case or being in high endemic areas, along with a tuberculin skin test and serum 
interferon gamma assay and chest x-rays, are recommended tools to determine 
the exposure risk and presence of the LTBI [110] [114]. Given their limitations, 
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the involvement of infectious disease specialists is therefore highly valuable for 
positive or indterminate results of tuberculin skin test or interferon gamma as- 
say or in cases with a history of exposure to a known open-TB case. Administra- 
tion of an immunosuppressant in such cases may lead to activation of dormant 
TB or a disseminated disease [110] [114]. 
Basic instructions for patients and family members to reduce respiratory tract, 
waterborne and foodborne infections in the community are recommended to 
sJIA patients on high-dose steroids or DMARDs, especially biologics [110] [115]. 
These instructions include practicing hand hygiene, avoiding contact with sick 
individuals, reducing one’s exposure to crowded confined places, drinking from 
a safe water supply, avoiding non-pasteurized milk, dairy products or juices, 
avoiding undercooked meat, seafood or eggs and limiting contact with animals 
[115]. 
Children on immunosuppressants should be seen and assessed by a physician 
if they develop fever or become unwell. Treatment should begin accordingly and 
promptly, and completion of blood count (CBC) and CRP/ESR at least should be 
done to rule out neutropenia and signs of MAS [4] [110]. Signs of adrenal gland 
inadequacy should be sought and evaluated for children with chronic use of cor- 
ticosteroids [69]. Decisions related to withholding biologics and other DMARDs 
should be discussed with a paediatric rheumatologist to assess for the possibility 
of sJIA flare-ups and the patient’s propensity for developing MAS [51] [57]. 
3) Monitoring of Growth, Development and Childhood Well-being 
Chronic inflammation due to sJIA and consequently long-term usage of cor- 
ticosteroids lead to a decrease of linear growth [69] [101] [116]. Since the start of 
the biological era, evidence has pointed to the beneficial effect of biologics on 
growth velocity especially tocilizumab [78], probably because of better disease 
and inflammation control and reduction of corticosteroid usage. Obesity or be- 
ing underweight may be observed with sJIA because of chronic usage of steroids 
or ongoing inflammation, respectively [69] [116]. In a cohort of more than 1000 
JIA patients, including 77 systemic JIA patients, there were a higher 3-year cu- 
mulative incidences, 9% for new-onset short stature and 34% for obesity [117]. 
Pubertal delay also is commonly encountered among patients with sJIA [118]. 
Children and families confronting sJIA may experience uncertainty, fear, 
overreaction and frustration [119] [120] [121]. Low quality-of-life scores, high 
pain scores, and elevated anxiety and depression scores are commonly reported 
in JIA [119] [120] [121]. The caring health team should communicate with pa- 
tients and families to explore any emotional, social or academic difficulty caused 
by JIA, its complications, needed treatments and infusions and appointments. 
13. Conclusion 
Early identification and diagnosis of sJIA rely on consideration of it in cases with 
fever, articular and cutaneous symptoms and exclusion of mimicker conditions. 
Early recognition of sJIA and proper treatment with corticosteroids or biologics 
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have shown to be beneficial to control the cytokine storm associated with sJIA. 
Care of patients with sJIA is complex; thus, a multidisciplinary team and aware- 
ness of the disease and its complications are important to monitor the disease 
and long-term morbidity and mortality. 
Author Contributions 





Consent for Publication 
Not applicable. 
 
Availability of Data 
Not applicable. 
 
Conflicts of Interest 
The author declares that there are no competing interests and no funding sup- 
port required for this review. 
References 
[1] Petty, R., Southwood, T., Manners, P., Baum, J., Glass, D., Goldenberg, J., et al. (2001) 
International League of Associations for Rheumatology Classification of Juvenile Idi- 
opathic Arthritis: Second Revision, Edmonton, 2001. The Journal of Rheumatology, 
31, 390-392. 
[2] Vastert, S.J., Jamilloux, Y., Quartier, P., Ohlman, S., Osterling-Koskinen, L., 
Kullenberg, T., et al. (2019) Anakinra in Children and Adults with Still’s Disease. 
Rheumatology, 58, vi9-vi22. https://doi.org/10.1093/rheumatology/kez350 
[3] Li, S., Zheng, S.T., Tang, SL., Pan, Y.L., Zhang, S., Fang, H. and Qiao, J.J. (2020) 
Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Dis- 
ease. Clinical Reviews in Allergy and Immunology, 58, 71-81. 
https://doi.org/10.1007/s12016-019-08747-8 
[4] Lee, J.J.Y. and Schneider, R. (2018) Systemic Juvenile Idiopathic Arthritis. Pediatric 
Clinics of North America, 65, 691-709. https://doi.org/10.1016/j.pcl.2018.04.005 
[5] ter Haar, N.M., van Dijkhuizen, E.H.P., Swart, J.F., van Royen-Kerkhof, A., el Idrissi, 
A., Leek, A.P., et al. (2019) Treatment to Target Using Recombinant Interleukin-1 
Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idi- 
opathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis & Rheuma- 
tology, 71, 1163-1173. https://doi.org/10.1002/art.40865 
[6] Ravelli, A., Consolaro, A., Horneff, G., Laxer, R.M., Lovell, D.J., Wulffraat, N.M., et 
al. (2018) Treating Juvenile Idiopathic Arthritis to Target: Recommendations of an 
International Task Force. Annals of the Rheumatic Diseases, 77, 819-828. 
https://doi.org/10.1136/annrheumdis-2018-213030 
[7] Giancane, G. and Ruperto, N. (2019) Treatment of Juvenile Idiopathic Arthritis: 
DOI: 10.4236/ojped.2020.104078 791 Open Journal of Pediatrics  
A. R. Albaker 
 
What’s New? Current Opinion in Rheumatology, 31, 428-435. 
https://doi.org/10.1097/BOR.0000000000000632 
[8] Thierry, S., Fautrel, B., Lemelle, I. and Guillemin, F. (2014) Prevalence and Inci- 
dence of Juvenile Idiopathic Arthritis: A Systematic Review. Joint Bone Spine, 81, 
112-117. https://doi.org/10.1016/j.jbspin.2013.09.003 
[9] Beukelman, T., Ringold, S., Davis, T.E., DeWitt, E.M., Pelajo, C.F., Weiss, P.F., et al. 
(2012) Disease-Modifying Anti-Rheumatic Drug Use in the Treatment of Juvenile 
Idiopathic Arthritis: A Cross-Sectional Analysis of the CARRA Registry. Journal of 
Rheumatology, 39, 1867-1874. https://doi.org/10.3899/jrheum.120110 
[10] Behrens, E.M., Beukelman, T., Gallo, L., Spangler, J., Rosenkranz, M., Arkachaisri, T., 
et al. (2008) Evaluation of the Presentation of Systemic Onset Juvenile Rheumatoid 
Arthritis: Data from the Pennsylvania Systemic-Onset Juvenile Arthritis Registry 
(PASOJAR). Journal of Rheumatology, 35, 343-348. 
[11] Consolaro, A., Giancane, G., Alongi, A., Van Dijkhuizen, E.H.P., Aggarwal, A., Bo- 
vis, F., et al. (2019) Phenotypic Variability and Disparities in Treatment and Out- 
comes of Childhood Arthritis throughout the World: Results from the EPOCA 
Study. Lancet Child & Adolescent Health, 3, 255-263. 
[12] Al-Hemairi, M.H., Albokhari, S.M. and Muzaffer, M.A. (2016) The Pattern of Juve- 
nile Idiopathic Arthritis in a Single Tertiary Center in Saudi Arabia. International 
Journal of Inflammation, 2016, Article ID: 7802957. 
https://doi.org/10.1155/2016/7802957 
[13] Berthold, E., Månsson, B. and Kahn, R. (2019) Outcome in Juvenile Idiopathic Arthri- 
tis: A Population-Based Study from Sweden. Arthritis Research & Therapy, 21, Article 
Number: 218. https://doi.org/10.1186/s13075-019-1994-8 
[14] Muzaffer, M.A., Turkistani, A., Alahmadi, L.S. and Sangoof, S. (2019) A 10-Year 
Saudi Experience of Using Adalimumab in Treating Juvenile Idiopathic Arthritis. 
Open Journal of Rheumatology and Autoimmune Diseases, 9, 42-56. 
[15] Abdwani, R., Abdalla, E., Al Abrawi, S. and Al-Zakwani, I. (2015) Epidemiology of 
Juvenile Idiopathic Arthritis in Oman. Pediatric Rheumatology, 13, Article No. 33. 
https://doi.org/10.1186/s12969-015-0030-z 
[16] Janow, G., Schanberg, L.E., Setoguchi, S., Hasselblad, V., Mellins, E.D., Schneider, 
R., et al. (2016) The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood 
Arthritis and Rheumatology Research Alliance Registry: 2010-2013. The Journal of 
Rheumatolog, 43, 1755-1762. https://doi.org/10.3899/jrheum.150997 
[17] Le, K. (2021). Armed Conflict and Child Weight in DR Congo. Advances in Public 
Health, 2021. https://doi.org/10.1155/2021/6931096 
[18] Vandenhaute, J., Avau, A., Filtjens, J., Malengier-Devlies, B., Imbrechts, M., Van 
den Berghe, N., et al. (2019) Regulatory Role for NK Cells in a Mouse Model of Sys- 
temic Juvenile Idiopathic Arthritis. Journal of Immunology, 203, 3339-3348. 
https://doi.org/10.4049/jimmunol.1900510 
[19] Le, K., & Nguyen, M. (2020). Shedding light on maternal education and child health 
in developing countries. World Development, 133, 105005. 
https://doi.org/10.1016/j.worlddev.2020.105005 
[20] Takakura, M., Shimizu, M., Yakoyama, T., Mizuta, M. and Yachie, A. (2018) Tran- 
sient Natural Killer Cell Dysfunction Associated with Interleukin-18 Overproduc- 
tion in Systemic Juvenile Idiopathic Arthritis. Pediatrics International, 60, 984-985. 
https://doi.org/10.1111/ped.13679 
[21] Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., et al. (2011) 
DOI: 10.4236/ojped.2020.104078 792 Open Journal of Pediatrics  
A. R. Albaker 
 
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial with the Inter- 
leukin-1 Receptor Antagonist Anakinra in Patients with Systemic-Onset Juvenile Idi- 
opathic Arthritis (ANAJIS Trial). Annals of the Rheumatic Diseases, 70, 747-754. 
https://doi.org/10.1136/ard.2010.134254 
[22] De Benedetti, F., Brunner, H.I., Ruperto, N., Kenwright, A., Wright, S., Calvo. I., et 
al. (2012) Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthri- 
tis. New England Journal of Medicine, 367, 2385-2395. 
https://doi.org/10.1056/NEJMoa1112802 
[23] Imbrechts, M., Avau, A., Vandenhaute, J., Malengier-Devlies, B., Put, K., Mitera, T., et 
al. (2018) Insufficient IL-10 Production as a Mechanism Underlying the Pathogenesis 
of Systemic Juvenile Idiopathic Arthritis. Journal of Immunology, 201, 2654-2663. 
https://doi.org/10.4049/jimmunol.1800468 
[24] Brown, R.A., Henderlight, M., Do, T., Yasin, S., Grom, A.A., DeLay, M., et al. (2018) 
Neutrophils from Children with Systemic Juvenile Idiopathic Arthritis Exhibit Per- 
sistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Dis- 
ease. Frontiers in Immunology, 9, 2995. https://doi.org/10.3389/fimmu.2018.02995 
[25] Pardeo, M., Bracaglia, C. and De Benedetti, F. (2017) Systemic Juvenile Idiopathic 
Arthritis: New Insights into Pathogenesis and Cytokine Directed Therapies. Best 
Practice & Research Clinical Rheumatology, 31, 505-516. 
https://doi.org/10.1016/j.berh.2018.02.002 
[26] Ombrello, M.J., Remmers, E.F., Tachmazidou, I., Grom, A., Foell, D., Haas, J.P., et 
al. (2015) HLA-DRB1∗11 and Variants of the MHC Class II Locus Are Strong Risk 
Factors for Systemic Juvenile Idiopathic Arthritis. Proceedings of National Acade- 
my of Sciences of the United States of America, 112, 15970-15975. 
https://doi.org/10.1073/pnas.1520779112 
[27] Ombrello, M.J., Arthur, V.L., Remmers, E.F., Hinks, A., Tachmazidou, I., Grom, 
A.A., et al. (2017) Genetic Architecture Distinguishes Systemic Juvenile Idiopathic 
Arthritis from Other Forms of Juvenile Idiopathic Arthritis: Clinical and Therapeu- 
tic Implications. Annals of the Rheumatic Diseases, 76, 906-913. 
https://doi.org/10.1136/annrheumdis-2016-210324 
[28] Henderson, L.A., Hoyt, K.J., Lee, P.Y., Rao, D.A., Helena Jonsson, A., Nguyen, J.P., 
et al. (2020) Th17 Reprogramming of T Cells in Systemic Juvenile Idiopathic Arth- 
ritis. JCI Insight, 5, e132508. https://doi.org/10.1172/jci.insight.132508 
[29] Wakil, S.M., Monies, D.M., Abouelhoda, M., Al-Tassan, N., Al-Dusery, H., Naim, 
E.A., et al. (2015) Association of a Mutation in LACC1 with a Monogenic Form of 
Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology, 67, 288-295. 
https://doi.org/10.1002/art.38877 
[30] Skon-Hegg, C., Zhang, J., Wu, X., Sagolla, M., Ota, N., Wuster, A., et al. (2019) 
LACC1 Regulates TNF and IL-17 in Mouse Models of Arthritis and Inflammation. 
Journal of Immunology, 202, 183-193. 
https://doi.org/10.4049/jimmunol.1800636 
[31] Martini, A., Ravelli, A., Avcin, T., Beresford, M.W., Burgos-Vargas, R., Cuttica, R., 
et al. (2019) Toward New Classification Criteria for Juvenile Idiopathic Arthritis: 
First Steps, Pediatric Rheumatology International Trials Organization International 
Consensus. Journal of Rheumatology, 46, 190-197. 
https://doi.org/10.3899/jrheum.180168 
[32] Le, K., & Nguyen, M. (2021). In-utero Exposure to Rainfall Variability and Early 
Childhood Health. World Development, 144, 105485. 
https://doi.org/10.1016/j.worlddev.2021.105485 
DOI: 10.4236/ojped.2020.104078 793 Open Journal of Pediatrics  
A. R. Albaker 
 
[33] Gohar, F., Mcardle, A., Jones, M., Callan, N., Hernandez, B., Kessel, C., et al. (2019) 
Molecular Signature Characterisation of Different Inflammatory Phenotypes of Sys- 
temic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 78, 1107-1113. 
https://doi.org/10.1136/annrheumdis-2019-215051 
[34] Hinze, C.H., Holzinger, D., Lainka, E., Haas, J.P., Speth, F., Kallinich, T., et al. 
(2018) Practice and Consensus-Based Strategies in Diagnosing and Managing Sys- 
temic Juvenile Idiopathic Arthritis in Germany. Pediatric Rheumatology, 16, Article 
No. 7. https://doi.org/10.1186/s12969-018-0224-2 
[35] Stephan, J.L. (2001) Reactive Haemophagocytic Syndrome in Children with In- 
flammatory Disorders. A Retrospective Study of 24 Patients. Rheumatology, 40, 
1285-1292. https://doi.org/10.1093/rheumatology/40.11.1285 
[36] Larson, A.R., Laga, A.C. and Granter, S.R. (2015) The Spectrum of Histopathologic 
Findings in Cutaneous Lesions in Patients with Still Disease. American Journal of 
Clinical Pathology, 144, 945-951. https://doi.org/10.1309/AJCPZE77UAPSMDCD 
[37] Frosch, M., Metze, D., Foell, D., Vogl, T., Sorg, C., Sunderkötter, C. and Roth, J. 
(2005) Early Activation of Cutaneous Vessels and Epithelial Cells Is Characteristic 
of Acute Systemic Onset Juvenile Idiopathic Arthritis. Experimental Dermatology, 
14, 259-265. https://doi.org/10.1111/j.0906-6705.2005.00271.x 
[38] Kadavath, S. and Efthimiou, P. (2015) Adult-Onset Still’s Disease-Pathogenesis, 
Clinical Manifestations, and New Treatment Options. Annals of Medicine, 47, 6-14. 
https://doi.org/10.3109/07853890.2014.971052 
[39] Batthish, M., Feldman, B.M., Babyn, P.S., Tyrrell, P.N. and Schneider, R. (2011) 
Predictors of Hip Disease in the Systemic Arthritis Subtype of Juvenile Idiopathic 
Arthritis. Journal of Rheumatology, 38, 954-958. 
https://doi.org/10.3899/jrheum.101146 
[40] Argyropoulou, M.I., Margariti, P.N., Karali, A., Astrakas, L., Alfandaki, S., Kosta, P., 
et al. (2009) Temporomandibular Joint Involvement in Juvenile Idiopathic Arthritis: 
Clinical Predictors of Magnetic Resonance Imaging Signs. European Radiology, 19, 
693-700. https://doi.org/10.1007/s00330-008-1196-2 
[41] Sandborg, C., Holmes, T.H., Lee, T., Biederman, K., Bloch, D.A., Emery, H., et al. 
(2006) Candidate Early Predictors for Progression to Joint Damage in Systemic Ju- 
venile Idiopathic Arthritis. Journal of Rheumatology, 33, 2322-2329. 
[42] Minoia, F., Bovis, F., Davì, S., Horne, A.C., Fischbach, M., Frosch, M., et al. (2019) 
Development and Initial Validation of the MS Score for Diagnosis of Macrophage Ac- 
tivation Syndrome in Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic 
Diseases, 78, 1357-1362. https://doi.org/10.1136/annrheumdis-2019-215211 
[43] Schulert, G.S., Yasin, S., Carey, B., Chalk, C., Do, T., Schapiro, A.H., et al. (2019) 
Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization 
and Risk Factors. Arthritis & Rheumatology, 71, 1943-1954. 
https://doi.org/10.1002/art.41073 
[44] Saper, V.E., Chen, G., Deutsch, G.H., Guillerman, R.P., Birgmeier, J., Jagadeesh, K., 
et al. (2019) Emergent High Fatality Lung Disease in Systemic Juvenile Arthritis. 
Annals of the Rheumatic Diseases, 78, 1722-1731. 
https://doi.org/10.1136/annrheumdis-2019-216040 
[45] Lefèvre-utile, A., Galeotti, C. and Koné-paut, I. (2014) Coronary Artery Abnormalities 
in Children with Systemic-Onset Juvenile Idiopathic Arthritis. Joint Bone Spine, 81, 
257-259. https://doi.org/10.1016/j.jbspin.2013.09.004 
[46] Dong, S., Bout-Tabaku, S., Texter, K. and Jaggi, P. (2015) Diagnosis of Systemic-Onset 
Juvenile Idiopathic Arthritis after Treatment for Presumed Kawasaki Disease. Journal 
DOI: 10.4236/ojped.2020.104078 794 Open Journal of Pediatrics  
A. R. Albaker 
 
of Pediatrics, 166, 1283-1288. https://doi.org/10.1016/j.jpeds.2015.02.003 
[47] Oh, K.J., Kwon, H.W., Cho, S. and Seo, J.W. (2020) A Case of Life-Threatening 
Valvulitis Mimicking Infective Endocarditis in Systemic Juvenile Idiopathic Arthri- 
tis. Cardiology in the Young, 30, 728-731. 
https://doi.org/10.1017/S1047951120000608 
[48] Chantarogh, S., Vilaiyuk, S., Tim-Aroon, T. and Worawichawong, S. (2017) Clinical 
Improvement of Renal Amyloidosis in a Patient with Systemic-Onset Juvenile Idi- 
opathic Arthritis Who Received Tocilizumab Treatment: A Case Report and Lite- 
rature Review. BMC Nephrology, 18, Article No. 159. 
https://doi.org/10.1186/s12882-017-0573-y 
[49] Delplanque, M., Pouchot, J., Ducharme-Bénard, S., Fautrel, B.J., Benyamine, A., 
Daniel, L., et al. (2020) AA Amyloidosis Secondary to Adult Onset Still’s Disease: 
about 19 Cases. Seminars in Arthritis and Rheumatism, 50, 156-165. 
https://doi.org/10.1016/j.semarthrit.2019.08.005 
[50] Cantarini, L., Lucherini, O.M., Simonini, G., Galeazzi, M., Baldari, C.T. and Cimaz, 
R. (2012) Systemic-Onset Juvenile Idiopathic Arthritis Complicated by Early Onset 
Amyloidosis in a Patient Carrying a Mutation in the MEFV Gene. Rheumatology 
International, 32, 465-467. https://doi.org/10.1007/s00296-009-1331-7 
[51] Ravelli, A., Grom, A.A., Behrens, E.M. and Cron, R.Q. (2012) Macrophage Activa- 
tion Syndrome as Part of Systemic Juvenile Idiopathic Arthritis: Diagnosis, Genet- 
ics, Pathophysiology and Treatment. Genes & Immunity, 13, 289-298. 
https://doi.org/10.1038/gene.2012.3 
[52] Henderson, L.A. and Cron, R.Q. (2020) Macrophage Activation Syndrome and 
Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Dis- 
orders: Diagnosis and Management. Pediatric Drugs, 22, 29-44. 
https://doi.org/10.1007/s40272-019-00367-1 
[53] Le, K., & Nguyen, M. (2021). The Impacts of Temperature Shocks on Birth Weight 
in Vietnam. Population and Development Review. 
https://doi.org/10.1111/padr.12428 
[54] Minoia, F., Davì, S., Horne, A., Demirkaya, E., Bovis, F., Li, C., et al. (2014) Clinical 
Features, Treatment, and Outcome of Macrophage Activation Syndrome Compli- 
cating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 
362 Patients. Arthritis & Rheumatology, 66, 3160-3169. 
https://doi.org/10.1002/art.38802 
[55] Behrens, E.M., Canna, S.W., Slade, K., Rao, S., Kreiger, P.A., Paessler, M., et al. (2011) 
Repeated TLR9 Stimulation Results in Macrophage Activation Syndrome: Like Dis- 
ease in Mice. Journal of Clinical Investigation, 121, 2264-2277. 
https://doi.org/10.1172/JCI43157 
[56] Eloseily, E.M.A., Minoia, F., Crayne, C.B., Beukelman, T., Ravelli, A. and Cron, R.Q. 
(2019) Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify 
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. ACR 
Open Rheumatology, 1, 345-349. https://doi.org/10.1002/acr2.11048 
[57] Ravelli, A., Minoia, F., Davì, S., Horne, A.C., Bovis, F., Pistorio, A., et al. (2016) 2016 
Classification Criteria for Macrophage Activation Syndrome Complicating Systemic 
Juvenile Idiopathic Arthritis: A European League against Rheumatism/American 
College of Rheumatology/Paediatric Rheumatology International Trials Organisa- 
tion Collaboration. Annals of the Rheumatic Diseases, 75, 481-489. 
https://doi.org/10.1136/annrheumdis-2015-208982 
[58] Hutchinson, M., Tattersall, R.S. and Manson, J.J. (2019) Haemophagocytic Lym- 
DOI: 10.4236/ojped.2020.104078 795 Open Journal of Pediatrics  
A. R. Albaker 
 
phohisticytosis—An Underrecognized Hyperinflammatory Syndrome. Rheumatol- 
ogy, 58, vi23-vi30. https://doi.org/10.1093/rheumatology/kez379 
[59] Jelušić, M., Kronja, M., Frković, M., Sršen, S., Frković, S.H. and Novački, K.Š. 
(2018) Comparison of Different Diagnostic Guidelines for the Diagnosis of Macro- 
phage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: 
Single Centre Experience. Acta Clinica Croatica, 57, 307-311. 
https://doi.org/10.20471/acc.2018.57.02.11 
[60] Minoia, F. and Ravelli, A. (2019) Fostering the Application of the MS Score in Sys- 
temic Juvenile Idiopathic Arthritis. Response to: “MS Score in Systemic Juvenile 
Idiopathic Arthritis: Suitable for Routine Use?” by Chi et al. Annals of the Rheu- 
matic Diseases. https://doi.org/10.1136/annrheumdis-2019-216067 
[61] Schulert, G.S., Minoia, F., Bohnsack, J., Cron, RQ, Hashad, S., KonÉ-Paut, I., et al. 
(2018) Effect of Biologic Therapy on Clinical and Laboratory Features of Macro- 
phage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. 
Arthritis Care & Research, 70, 409-419. https://doi.org/10.1002/acr.23277 
[62] Behrens, E.M., Beukelman, T., Paessler, M. and Cron, R.Q. (2007) Occult Macro- 
phage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis. 
Journal of Rheumatology, 34, 1133-1138. 
[63] Çakan, M., Karadağ, Ş.G., Tanatar, A. and Ayaz, N.A. (2019) The Frequency of Ma- 
crophage Activation Syndrome and Disease Course in Systemic Juvenile Idiopathic 
Arthritis. Modern Rheumatology, 30, 900-904. 
https://doi.org/10.1080/14397595.2019.1660026 
[64] Shenoi, S. and Wallace, C.A. (2016) Diagnosis and Treatment of Systemic Juvenile 
Idiopathic Arthritis. Journal of Pediatrics, 177, 19-26. 
https://doi.org/10.1016/j.jpeds.2016.06.056 
[65] Aljaberi, N., Tronconi, E., Schulert, G., Grom, A.A., Lovell, D.J., Huggins, J.L., et al. 
(2020) The Use of S100 Proteins Testing in Juvenile Idiopathic Arthritis and Au- 
toinflammatory Diseases in a Pediatric Clinical Setting: A Retrospective Analysis. 
Pediatric Rheumatology, 18, Article No. 7. 
https://doi.org/10.1186/s12969-020-0398-2 
[66] Arduini, A., Marasco, E., Marucci, G., Pardeo, M., Insalaco, A., Caiello, I., et al. 
(2019) An Unusual Presentation of Purine Nucleoside Phosphorylase Deficiency 
Mimicking Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Ac- 
tivation Syndrome. Pediatric Rheumatology, 17, Article No. 25. 
https://doi.org/10.1186/s12969-019-0328-3 
[67] Consolaro, A., Bracciolini, G., Ruperto, N., Pistorio, A., Magni-Manzoni, S., Malattia, 
C., et al. (2012) Remission, Minimal Disease Activity, and Acceptable Symptom State 
in Juvenile Idiopathic Arthritis: Defining Criteria Based on the Juvenile Arthritis 
Disease Activity Score. Arthritis & Rheumatism, 64, 2366-2374. 
https://doi.org/10.1002/art.34373 
[68] De Witt, E.M., Kimura, Y., Beukelman, T., Nigrovic, P.A., Onel, K., Prahalad, S., et 
al. (2012) Consensus Treatment Plans for New-Onset Systemic Juvenile Idiopathic 
Arthritis. Arthritis Care & Research, 64, 1001-1010. 
https://doi.org/10.1002/acr.21625 
[69] Vannucci, G., Cantarini, L., Giani, T., Marrani, E., Moretti, D., Pagnini, I., et al. 
(2013) Glucocorticoids in the Management of Systemic Juvenile Idiopathic Arthri- 
tis. Pediatric Drugs, 15, 343-349. https://doi.org/10.1007/s40272-013-0038-0 
[70] Vastert, S.J. and Nigrovic, P.A. (2018) Editorial: Toward Personalized Treatment for 
Systemic Juvenile Idiopathic Arthritis. Arthritis & Rheumatology, 70, 1172-1174. 
DOI: 10.4236/ojped.2020.104078 796 Open Journal of Pediatrics  
A. R. Albaker 
 
https://doi.org/10.1002/art.40501 
[71] Spiegel, L.R., Schneider, R., Lang, B.A., Birdi, N., Silverman, E.D., Laxer, R.M., et al. 
(2000) Early Predictors of Poor Functional Outcome in Systemic-Onset Juvenile 
Rheumatoid Arthritis A Multicenter Cohort Study. Arthritis & Rheumatology, 43, 
2402-2409. 
https://doi.org/10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C 
[72] Vitale, A., Cavalli, G., Ruscitti, P., Sota, J., Colafrancesco, S., Priori, R., et al. (2020) 
Comparison of Early vs. Delayed Anakinra Treatment in Patients with Adult Onset 
Still’s Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medi- 
cine, 7, 42. https://doi.org/10.3389/fmed.2020.00042 
[73] Pardeo, M., Marafon, D.P., Insalaco, A., Bracaglia, C., Nicolai, R., Messia, V., et al. 
(2015) Anakinra in Systemic Juvenile Idiopathic arthritis: A Single-Center Expe- 
rience. Journal of Rheumatology, 42, 1523-1527. 
https://doi.org/10.3899/jrheum.141567 
[74] Saccomanno, B., Tibaldi, J., Minoia, F., Bagnasco, F., Pistorio, A., Guariento, A., et 
al. (2019) Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic 
Arthritis. Journal of Rheumatology, 46, 416-421. 
https://doi.org/10.3899/jrheum.180331 
[75] Pascual, V., Allantaz, F., Arce, E., Punaro, M. and Banchereau, J. (2005) Role of In- 
terleukin-1 (IL-1) in the Pathogenesis of Systemic Onset Juvenile Idiopathic Arthri- 
tis and Clinical Response to IL-1 Blockade. Journal of Experimental Medicine, 201, 
1479-1486. https://doi.org/10.1084/jem.20050473 
[76] Ruperto, N., Brunner, H.I., Quartier, P, Constantin, T., Wulffraat, N., Horneff, G., 
et al. (2012) Two Randomized Trials of Canakinumab in Systemic Juvenile Idi- 
opathic Arthritis. Journal of Experimental Medicine, 367, 2396-2406. 
https://doi.org/10.1056/NEJMoa1205099 
[77] Ruperto, N., Brunner, H.I., Quartier, P., Constantin, T., Wulffraat, N.M., Horneff, 
G., et al. (2018) Canakinumab in Patients with Systemic Juvenile Idiopathic Arthri- 
tis and Active Systemic Features: Results from the 5-Year Long-Term Extension of 
the Phase III Pivotal Trials. Annals of the Rheumatic Diseases, 77, 1710-1719. 
https://doi.org/10.1136/annrheumdis-2018-213150 
[78] De Benedetti, F., Brunner, H., Ruperto, N., Schneider, R., Xavier, R., Allen, R., et al. 
(2015) Catch-Up Growth during Tocilizumab Therapy for Systemic Juvenile Idiopathic 
Arthritis: Results from a Phase III Trial. Arthritis & Rheumatology, 67, 840-848. 
https://doi.org/10.1002/art.38984 
[79] Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., et al. (2008) 
Efficacy and Safety of Tocilizumab in Patients with Systemic-Onset Juvenile Idi- 
opathic Arthritis: A Randomised, Double-Blind, Placebo-Controlled, Withdrawal 
Phase III Trial. Lancet, 371, 998-1006. 
https://doi.org/10.1016/S0140-6736(08)60454-7 
[80] Mallalieu, N.L., Wimalasundera, S., Hsu, J.C., Douglass, W., Wells, C., Penades, I.C., 
et al. (2019) Intravenous Dosing of Tocilizumab in Patients Younger than Two Years 
of Age with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Phase 
1 Clinical Trial. Pediatric Rheumatology, 17, Article No. 57. 
https://doi.org/10.1186/s12969-019-0364-z 
[81] Pardeo, M., Wang, J., Ruperto, N., Alexeeva, E., Chasnyk, V., Schneider, R., et al. 
(2019) Neutropenia during Tocilizumab Treatment Is Not Associated with Infec- 
tion Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis. Journal 
of Rheumatology, 46, 1117-1126. https://doi.org/10.3899/jrheum.180795 
DOI: 10.4236/ojped.2020.104078 797 Open Journal of Pediatrics  
A. R. Albaker 
 
[82] Leurs, A., Launay, D., Terriou, L., Hatron, P.-Y., Quartier, P. and Hachulla, E. 
(2018) Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis after 
Treatment with Siltuximab. Journal of Clinical Rheumatology, 25, e40-e42. 
https://doi.org/10.1097/RHU.0000000000000716 
[83] ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
(2016) Identifier NCT02991469. A Repeated Dose-Finding Study of Sarilumab in 
Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (SKYPS). 
https://clinicaltrials.gov/ct2/show/NCT02991469?cond=sarilumab&draw=4&rank= 
24 
[84] Sura, A., Failing, C., Sturza, J., Stannard, J. and Riebschleger, M. (2018) Patient 
Characteristics Associated with Response to NSAID Monotherapy in Children with 
Systemic Juvenile Idiopathic Arthritis. Pediatric Rheumatology, 16, Article No. 2. 
https://doi.org/10.1186/s12969-017-0219-4 
[85] Woo, P., Southwood, T.R., Prieur, A.M., Doré, C.J., Grainger, J., David, J., et al. 
(2000) Randomized, Placebo-Controlled, Crossover Trial of Low-Dose Oral Metho- 
trexate in Children with Extended Oligoarticular or Systemic Arthritis. Arthritis & 
Rheumatism, 43, 1849-1857. 
https://doi.org/10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F 
[86] Bava, C., Mongelli, F., Pistorio, A., Bertamino, M., Bracciolini, G., Dalprà, S., et al. 
(2019) A Prediction Rule for Lack of Achievement of Inactive Disease with Metho- 
trexate as the Sole Disease-Modifying Antirheumatic Therapy in Juvenile Idiopathic 
Arthritis. Pediatric Rheumatology, 17, Article No. 50. 
https://doi.org/10.1186/s12969-019-0355-0 
[87] Ruperto, N., Ravelli, A., Castell, E., Gerloni, V., Haefner, R., Malattia, C., et al. (2006) 
Cyclosporine A in Juvenile Idiopathic Arthritis. Results of the PRCSG/PRINTO Phase 
IV Post Marketing Surveillance Study. Clinical and Experimental Rheumatology, 24, 
599-605. 
[88] Pal, P., Giri, P.P. and Sinha, R. (2019) Cyclosporine in Resistant Systemic Arthri- 
tis—A Cheaper Alternative to Biologics. Indian Journal of Pediatrics, 86, 590-594. 
https://doi.org/10.1007/s12098-019-02912-9 
[89] Zhao, Z., Ye, C. and Dong, L. (2020) The Off-Label Uses Profile of Tofacitinib in 
Systemic Rheumatic Diseases. International Immunopharmacology, 83, Article ID: 
106480. https://doi.org/10.1016/j.intimp.2020.106480 
[90] Huang, Z.X., Lee, P.Y., Yao, X.Y., Zheng, S.L. and Li, T.W. (2019) Tofacitinib Treat- 
ment of Refractory Systemic Juvenile Idiopathic Arthritis. Pediatrics, 143, e20182845. 
https://doi.org/10.1542/peds.2018-2845 
[91] Bader-Meunier, B., Hadchouel, A., Berteloot, L., Polivka, L., Béziat, V., Casanova, 
J.L., et al. (2020) Effectiveness and Safety of Ruxolitinib for the Treatment of Re- 
fractory Systemic Idiopathic Juvenile Arthritis Like Associated with Interstitial Lung 
Disease: A Case Report. Annals of the Rheumatic Diseases. 
https://doi.org/10.1136/annrheumdis-2020-216983 
[92] ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
(2016) Identifier NCT03000439. A Safety, Efficacy and Pharmacokinetics Study of 




[93] Wang, D.D., Chen, X. and Li, Z.P. (2019) Treatment of Patients with System- ic-
Onset Juvenile Idiopathic Arthritis with Tacrolimus. Experimental and Thera- 
DOI: 10.4236/ojped.2020.104078 798 Open Journal of Pediatrics  
A. R. Albaker 
 
peutic Medicine, 17, 2305-2309. https://doi.org/10.3892/etm.2019.7174 
[94] Ringold, S. and Wallace, C.A. (2007) Measuring Clinical Response and Remission in 
Juvenile Idiopathic Arthritis. Current Opinion in Rheumatology, 19, 471-476. 
https://doi.org/10.1097/BOR.0b013e32825a6a68 
[95] Wallace, C.A., Huang, B., Bandeira, M., Ravelli, A. and Giannini, E.H. (2005) Pat- 
terns of Clinical Remission in Select Categories of Juvenile Idiopathic Arthritis. 
Arthritis & Rheumatism, 52, 3554-3562. https://doi.org/10.1002/art.21389 
[96] Ringold, S., Weiss, P.F., Beukelman, T., Dewitt, E.M., Ilowite, N.T., Kimura, Y., et 
al. (2013) 2013 Update of the 2011 American College of Rheumatology Recom- 
mendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations 
for the Medical Therapy of Children with Systemic Juvenile Idiopathic Arthritis and 
Tuberculosis Screening among Children Receiving Biologic Medications. Arthritis 
& Rheumatism, 65, 2499-2512. https://doi.org/10.1002/art.38092 
[97] Bielak, M., Husmann, E., Weyandt, N., Haas, J.P., Hügle, B., Horneff, G., et al. 
(2018) IL-6 Blockade in Systemic Juvenile Idiopathic Arthritis—Achievement of 
Inactive Disease and Remission (Data from the German AID-Registry). Pediatric 
Rheumatology, 16, Article No. 22. https://doi.org/10.1186/s12969-018-0236-y 
[98] Shenoi, S., Nanda, K., Schulert, G.S., Bohnsack, J.F., Cooper, A.M., Edghill, B., et al. 
(2019) Physician Practices for Withdrawal of Medications in Inactive Systemic Juve- 
nile Arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) 
Survey. Pediatric Rheumatology, 17, Article No. 48. 
https://doi.org/10.1186/s12969-019-0342-5 
[99] Hashkes, P.J., Wright, B.M., Lauer, M.S., Worley, S.E., Tang, A.S., Roettcher, P.A., 
et al. (2010) Mortality Outcomes in Pediatric Rheumatology in the US. Arthritis & 
Rheumatism, 62, 599-608. https://doi.org/10.1002/art.27218 
[100] Davies, R., Southwood, T., Kearsley-Fleet, L., Lunt, M., Baildam, E., Beresford, 
M.W., et al. (2017) Mortality Rates Are Increased in Patients with Systemic Juvenile 
Idiopathic Arthritis. Archives of Disease in Childhood, 102, 206-207. 
https://doi.org/10.1136/archdischild-2016-311571 
[101] Barut, K., Adrovic, A., Sahin, S., Tarcin, G., Tahaoglu, G., Koker, O., et al. (2019) 
Prognosis, Complications and Treatment Response in Systemic Juvenile Idiopathic 
Arthritis Patients: A Single-Center Experience. International Journal of Rheumatic 
Diseases, 22, 1661-1669. https://doi.org/10.1111/1756-185X.13649 
[102] Sağ, E., Uzunoğlu, B., Bal, F., Sönmez, H.E., Demir, S., Bilginer, Y., et al. (2019) 
Systemic Onset Juvenile Idiopathic Arthritis: A Single Center Experience. The Tur- 
kish Journal of Pediatrics, 61, 852-858. 
https://doi.org/10.24953/turkjped.2019.06.005 
[103] Bennett, T.D., Fluchel, M., Hersh, A.O., Hayward, K.N., Hersh, A.L., Brogan, T.V., et 
al. (2012) Macrophage Activation Syndrome in Children with Systemic Lupus Ery- 
thematosus and Juvenile Idiopathic Arthritis. Arthritis & Rheumatism, 64, 4135-4142. 
https://doi.org/10.1002/art.34661 
[104] Sawhney, S., Woo, P. and Murray, K.J. (2001) Macrophage Activation Syndrome: A 
Potentially Fatal Complication of Kawasaki Disease. Archives of Disease in Child- 
hood, 85, 421-426. https://doi.org/10.1136/adc.85.5.421 
[105] Singh-Grewal, D., Schneider, R., Bayer, N. and Feldman, B.M. (2006) Predictors of 
Disease Course and Remission in Systemic Juvenile Idiopathic Arthritis: Significance 
of Early Clinical and Laboratory Features. Arthritis & Rheumatism, 54, 1595-1601. 
https://doi.org/10.1002/art.21774 
[106] Tiller, G., Buckle, J., Allen, R., Munro, J., Gowdie, P., Cox, A., et al. (2018) Juvenile 
DOI: 10.4236/ojped.2020.104078 799 Open Journal of Pediatrics  
A. R. Albaker 
 
Idiopathic Arthritis Managed in the New Millennium: One Year Outcomes of an 
Inception Cohort of Australian Children. Pediatric Rheumatology, 16, Article No. 
69. https://doi.org/10.1186/s12969-018-0288-z 
[107] Glerup, M., Rypdal, V., Arnstad, E.D., Ekelund, M., Peltoniemi, S., Aalto, K., et al. 
(2020) Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of 
Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. 
Arthritis Care & Research, 72, 507-516. https://doi.org/10.1002/acr.23853 
[108] Chhabra, A., Robinson, C., Houghton, K., Cabral, D.A., Morishita, K., Tucker, L.B., et 
al. (2020) Long-Term Outcomes and Disease Course of Children with Juvenile Idi- 
opathic Arthritis in the ReACCh-Out Cohort : A Two-Centre Experience. Rheumatol- 
ogy, 59, 3727-3730. https://doi.org/10.1093/rheumatology/keaa118 
[109] Moore, D.L. (2018) Immunization of the Immunocompromised Child: Key Principles. 
Paediatrics & Child Health, 23, 203-205. https://doi.org/10.1093/pch/pxx180 
[110] Le Saux, N. (2012) Biologic Response Modifiers to Decrease Inflammation: Focus 
on Infection Risks. Paediatrics & Child Health, 17, 147-150. 
https://doi.org/10.1093/pch/17.3.147 
[111] Ramanan, A.V., Whitworth, P. and Baildam, E.M. (2003) Use of Methotrexate in 
Juvenile Idiopathic Arthritis. Archives of Disease in Childhood, 88, 197-200. 
https://doi.org/10.1136/adc.88.3.197 
[112] (2020) An Advisory Committee Statement (ACS) National Advisory Committee on 
Immunization Canadian Immunization Guide Chapter on Influenza and Statement 





[113] Cellucci, T., Guzman, J., Petty, R.E., Batthish, M., Benseler, S.M., Ellsworth, J.E., et 
al. (2016) Management of Juvenile Idiopathic Arthritis 2015: A Position Statement 
from the Pediatric Committee of the Canadian Rheumatology Association. Journal 
of Rheumatology, 43, 1773-1776. https://doi.org/10.3899/jrheum.160074 
[114] Le, K., & Nguyen, M. (2020). Armed conflict and birth weight. Economics & Human 
Biology, 39, 100921. https://doi.org/10.1016/j.ehb.2020.100921 
[115] Bridger, N.A. and Allen, U.D. (2019) Safe Living Strategies for the Immunocompro- 
mised Child. Paediatrics & Child Health, 24, 291. 
https://doi.org/10.1093/pch/pxz082 
[116] Bechtold, S. and Simon, D. (2014) Growth Abnormalities in Children and Adolescents 
with Juvenile Idiopathic Arthritis. Rheumatology International, 34, 1483-1488. 
https://doi.org/10.1007/s00296-014-3022-2 
[117] Guzman, J., Kerr, T., Ward, L.M., Ma, J., Oen, K., Rosenberg, A.M., et al. (2017) 
Growth and Weight Gain in Children with Juvenile Idiopathic Arthritis: Results 
from the ReACCh-Out Cohort. Pediatric Rheumatology, 15, Article No. 68. 
https://doi.org/10.1186/s12969-017-0196-7 
[118] Machado, S.H., Xavier, R.M., Lora, P.S., Gonçalves, L.M.K., Trindade, L.R. and 
Marostica, P.J.C. (2020) Height and Sexual Maturation in Girls with Juvenile Idi- 
opathic Arthritis. Jornal de Pediatria, 96, 100-107. 
https://doi.org/10.1016/j.jped.2018.07.015 
[119] Foster, H.E., Marshall, N., Myers, A., Dunkley, P. and Griffiths, I.D. (2003) Out- 
come in Adults with Juvenile Idiopathic Arthritis: A Quality of Life Study. Arthritis 
& Rheumatism, 48, 767-775. https://doi.org/10.1002/art.10863 
DOI: 10.4236/ojped.2020.104078 800 Open Journal of Pediatrics  
A. R. Albaker 
 
[120] Albokhari, S.M. and Muzaffer, M.A. (2019) Health-Related Quality of Life of 
Children and Adolescents with Juvenile Idiopathic Arthritis in Western Saudi Ara- 
bia. Open Journal of Rheumatology and Autoimmune Diseases, 9, 69-83. 
[121] Shaw, K.L., Southwood, T.R., Duffy, C.M. and McDonagh, J.E. (2006) Health-Related 
Quality of Life in Adolescents with Juvenile Idiopathic Arthritis. Arthritis Care & Re- 
search, 55, 199-207. https://doi.org/10.1002/art.21852 
DOI: 10.4236/ojped.2020.104078 801 Open Journal of Pediatrics  
A. R. Albaker 
 
Abbreviations 
sJIA: systemic juvenile idiopathic arthritis 
JIA: juvenile idiopathic arthritis 
ILAR: International League of Associations for Rheumatology 
DMARDs: disease-modifying antirheumatic drugs 
MAS: macrophage activation syndrome 
MeSH: Medical Subject Headings 
ACR: American College of Rheumatology 
CARRA: Childhood Arthritis and Rheumatology Research Alliance 
PRINTO: Pediatric Rheumatology International Trials Organizations 
IL: interleukin 
IFN-γ: interferon gamma 
TNF: tumour necrosis factor 
MHC: major histocompatibility complex 
IVIG: intravenous immunoglobulins 
KD: Kwasaki disease 
MEFV: Mediterranean fever gene 
HLH: hemophagocytic lymphohistocytosis 
TLR-9: toll-like receptor 9 
ESR: erythrocyte sedimentation test 
LDH: lactate dehydrogenase 
AST: aspartate aminotransferases 
ALT: alanine aminotransferases 
CRP: C-reactive protein 
LFT: liver function test 
CBC: complete blood count 
RFT: renal function test 
TCZ: tocilizumab 
NSAIDs: nonsteroidal anti-inflammatory drugs 
LTBI: latent tuberculosis infection 
TB: tuberculosis 
